Tucidinostat
As of the edition of 20 October 2026, Tucidinostat is a small molecule: marketed, first approved in 2021 (JP); acts on HDAC1, HDAC10 and HDAC2 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Hiyasta
- First approved
- 23 June 2021 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- HUYA JAPAN G.K.; 2 holders in all
- Registered trials
- 210, 6 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Digestive system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 0 | 5 | 0 |
| Phase 1 | 9 | 3 | 2 | 3 |
| Phase 2 | 169 | 18 | 67 | 3 |
| Phase 3 | 17 | 2 | 8 | 0 |
| Phase 4 | 2 | 0 | 0 | 0 |
| All trials | 210 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chipscreen Biosciences | Lead sponsor of trials | 2013 to now |
| Huyabio | Lead sponsor of trials | 2014 to now |